drugset / Trial / NCT00884286

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

NCT00884286

Phase 2 Completed 67 enrolled PharmaMar
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.

Timeline

Start
2004-12
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Plitidepsin Peptide 3.2 mg/m2 Intravenous

Indications